News
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) — Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice…
Share
Myriad Receives FDA Approval of myChoice CDx® as Companion Diagnostic for Lynparza™ (olaparib) In Patients with Advanced Ovarian Cancer
SALT LAKE CITY, May 11, 2020 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that the U.S. Food and Drug…
Share
CytoDyn to Present at Wall Street Reporter’s NEXT SUPERSTOCK Livestream Event on May 13, 2020 at 12:30 pm ET / 9:30 am PT
VANCOUVER, Washington, May 11, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5…
Share
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challengesConference Call and Webcast Scheduled Today at 8:00 AM ETWARMINSTER, Pa., May 11, 2020 (GLOBE…
Share
CytoDyn Clarifies Status of Biologics License Application
Additional Data Required to Complete Application Expected to be Submitted on May 11, 2020VANCOUVER, Washington, May 08, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or…
Share
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. —All six analyzed moderate-to-severe COVID-19…
Share
Novant Health Initiates Phase 2b/3 Trial with CytoDyn’s Leronlimab for Severely and Critically Ill COVID-19 Patients
FDA has approved 54 Emergency INDs to allow access to leronlimab for severely and critically ill COVID-19 patientsVANCOUVER, Washington and WINSTON-SALEM, N.C., May 07, 2020 (GLOBE…
Share
Manuscript Describes How CytoDyn’s Leronlimab Disrupts CCL5/RANTES-CCR5 Pathway, Thereby Restoring Immune Homeostasis, Reducing Plasma Viral Load, Reversing Hyper Immune Activation and Inflammation in Critical COVID-19 Patients
Manuscript Posted Online to Research Square and MedRxiv Pre-print ServerVANCOUVER, Washington, May 05, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a…
Share
Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19
MIAMI, May 05, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative…
Share
FDA Approves 54 Emergency INDs for Leronlimab Treatment of Coronavirus – CytoDyn Requests Compassionate Use from FDA for COVID-19 Patients Not Eligible for Participation in Two Ongoing Clinical Trials in U.S. – CytoDyn Targets Enrollment Completion for its 75 Patient, Phase 2 Trial by End of May
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5…
Share